Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

The introduction of small-molecule tyrosine kinase inhibitors (TKIs) in clinical oncology has
transformed the treatment of certain forms of cancers. As of 31 March 2013, 18 such agents …

OBJECTIVE: To report a case of imatinib-induced hepatotoxicity after concurrent ginseng
ingestion in a patient with chronic myelogenous leukemia (CML). CASE SUMMARY: A 26 …

Patients diagnosed with advanced gastrointestinal stromal tumor (GIST) are currently treated
with oral tyrosine kinase inhibitors (TKIs). Imatinib mesylate is the standard first-line …

Introduction: All anticancer drugs can cause idiosyncratic liver injury. Therefore,
hepatoprotective agents assume particular importance to preserve liver function. Hepatic …

Tyrosine kinases (TKs) is a family of tyrosine protein kinases with important functions in the
regulation of a broad variety of physiological cell processes. Overactivity of TK disturbs …

Introduction: Existing clinical evidence indicates that many tyrosine kinase inhibitors (TKIs)
are associated with idiosyncratic hepatotoxicity. TKIs possess risk factors for developing …

Drug‐induced liver injury (DILI) encompasses a spectrum of liver diseases from acute and
chronic hepatitis, cholestatic syndromes, and vascular lesions through to benign and …

Immunotherapy for cancer has undergone a rapid expansion in classes, agents, and
indications. By utilizing aspects of the body's innate immune system, immunotherapy has …

Aim The aim of this study is to investigate the incidence and risk of hepatic toxicity in patients
receiving tyrosine kinase inhibitors (TKIs) through a large up‐to‐date meta‐analysis of …